Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-04-2020 | Neuroendocrine Tumor | Original Article

The radiosensitizer Onalespib increases complete remission in ¹⁷⁷Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts

Authors: Sara Lundsten, Diana Spiegelberg, Nakul R. Raval, Marika Nestor

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2020

Abstract

Purpose

¹⁷⁷Lu-DOTATATE targeting the somatostatin receptor (SSTR) is utilized for treatment of neuroendocrine tumors (NETs). Onalespib, a heat shock protein 90 (HSP90) inhibitor, has demonstrated radiosensitizing properties and may thus enhance the effect of ¹⁷⁷Lu-DOTATATE. Consequently, the aim of this study was to assess the potential of Onalespib in combination with ¹⁷⁷Lu-DOTATATE in vivo and to examine the toxicity profiles of the treatments.

Methods

¹⁷⁷Lu-DOTATATE selectivity and distribution in NET xenografts were studied using biodistribution and autoradiography. Therapeutic effects of Onalespib in combination with ¹⁷⁷Lu-DOTATATE were studied in NET xenografts. Histological analyses were used to assess molecular effects from treatment and to establish toxicity profiles.

Results

Biodistribution and autoradiography confirmed the SSTR-selective tumor uptake of ¹⁷⁷Lu-DOTATATE, which was unaffected by Onalespib treatment. Immunohistochemistry verified molecular responses to Onalespib therapy in the tumors. While Onalespib and ¹⁷⁷Lu-DOTATATE monotherapies resulted in a 10% and 33% delay in tumor doubling time compared with control, the combination treatment resulted in a 73% delayed tumor doubling time. Moreover, combination treatment increased complete remissions threefold from ¹⁷⁷Lu-DOTATATE monotherapy, resulting in 29% complete remissions. In addition, histological analyses demonstrated radiation-induced glomerular injury in the ¹⁷⁷Lu-DOTATATE monotherapy group. The damage was decreased tenfold in the combination group, potentially due to Onalespib-induced HSP70 upregulation in the kidneys.

Conclusion

Treatment with Onalespib potentiated ¹⁷⁷Lu-DOTATATE therapy of NET xenografts with a favorable toxicity profile. Utilizing Onalespib’s radiosensitizing properties with ¹⁷⁷Lu-DOTATATE may lead to better therapeutic results in the future and may reduce unwanted side effects in dose-limiting organs.

Available only for authorised users

Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002.CrossRefPubMedPubMedCentral

Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33(16):1855–63. https://doi.org/10.1200/jco.2014.60.2532.CrossRefPubMed

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427.CrossRefPubMedPubMedCentral

Hankus J, Tomaszewska R. Neuroendocrine neoplasms and somatostatin receptor subtypes expression. Nucl Med Rev Cent East Eur. 2016;19(2):111–7. https://doi.org/10.5603/NMR.2016.0022.CrossRefPubMed

de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58(3):437–41.PubMed

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82. https://doi.org/10.1007/s002590050034.CrossRefPubMed

Drugs.com. FDA approves Lutathera (lutetium Lu 177 dotatate) for gastroenteropancreatic neuroendocrine tumors. 2018. https://www.drugs.com/newdrugs/fda-approves-lutathera-lutetium-lu-177-dotatate-gastroenteropancreatic-neuroendocrine-tumors-4686.html. Accessed 2019/05/01 2019.

Agency EM. Lutathera. 2017. https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera. Accessed 2019-04-13 2019.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30. https://doi.org/10.1200/JCO.2007.15.2553.CrossRefPubMed

10.

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754–62. https://doi.org/10.1200/JCO.2005.08.066.CrossRefPubMed

11.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35. https://doi.org/10.1007/s00259-011-1902-1.CrossRefPubMed

12.

Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2016;43(6):1040–6. https://doi.org/10.1007/s00259-015-3262-8.CrossRefPubMed

13.

Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51(7):1049–58. https://doi.org/10.2967/jnumed.110.075101.CrossRefPubMed

14.

Maier P, Hartmann L, Wenz F, Herskind C. Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization. Int J Mol Sci. 2016;17(1). https://doi.org/10.3390/ijms17010102.CrossRefPubMedCentral

15.

Spiegelberg D, Dascalu A, Mortensen AC, Abramenkovs A, Kuku G, Nestor M, et al. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells. Oncotarget. 2015;6(34):35652–66. https://doi.org/10.18632/oncotarget.5363.CrossRefPubMedPubMedCentral

16.

Hofving T, Sandblom V, Arvidsson Y, Shubbar E, Altiparmak G, Swanpalmer J, et al. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Endocr Relat Cancer. 2019;26(4):437–49. https://doi.org/10.1530/ERC-18-0509.CrossRefPubMedPubMedCentral

17.

Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013;39(4):375–87. https://doi.org/10.1016/j.ctrv.2012.10.001.CrossRefPubMed

18.

Pennisi R, Ascenzi P, di Masi A. Hsp90: a new player in DNA repair? Biomolecules. 2015;5(4):2589–618. https://doi.org/10.3390/biom5042589.CrossRefPubMedPubMedCentral

19.

Do K, Speranza G, Chang LC, Polley EC, Bishop R, Zhu W, et al. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Investig New Drugs. 2015;33(4):921–30. https://doi.org/10.1007/s10637-015-0255-1.CrossRef

20.

Shapiro GI, Kwak E, Dezube BJ, Yule M, Ayrton J, Lyons J, et al. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):87–97. https://doi.org/10.1158/1078-0432.ccr-14-0979.CrossRefPubMed

21.

Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC. Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010;53(1):3–17. https://doi.org/10.1021/jm9004708.CrossRefPubMed

22.

Zhou H, Kato A, Yasuda H, Odamaki M, Itoh H, Hishida A. The induction of heat shock protein-72 attenuates cisplatin-induced acute renal failure in rats. Pflugers Arch. 2003;446(1):116–24. https://doi.org/10.1007/s00424-002-0996-5.CrossRefPubMed

23.

Komatsuda A, Wakui H, Oyama Y, Imai H, Miura AB, Itoh H, et al. Overexpression of the human 72 kDa heat shock protein in renal tubular cells confers resistance against oxidative injury and cisplatin toxicity. Nephrol Dial Transplant. 1999;14(6):1385–90.CrossRefPubMed

24.

Yokoo T, Kitamura M. IL-1beta depresses expression of the 70-kilodalton heat shock protein and sensitizes glomerular cells to oxidant-initiated apoptosis. J Immunol. 1997;159(6):2886–92.PubMed

25.

Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, Ames MM. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas. 2013;42(3):411–21. https://doi.org/10.1097/MPA.0b013e31826cb243.CrossRefPubMedPubMedCentral

26.

Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, et al. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer. 2010;17(3):623–36. https://doi.org/10.1677/ERC-09-0318.CrossRefPubMed

27.

Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, et al. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol. 2012;40(5):1659–67. https://doi.org/10.3892/ijo.2012.1328.CrossRefPubMed

28.

Zitzmann K, Ailer G, Vlotides G, Spoettl G, Maurer J, Göke B, et al. Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. Int J Oncol. 2013;43(6):1824–32. https://doi.org/10.3892/ijo.2013.2130.CrossRefPubMedPubMedCentral

29.

Spiegelberg D, Lundsten S, Mortensen AC, Abramenkovs A, Stenerlöw B, Nestor M. In vitro and in vivo growth inhibitory and radiosensitizing effects of the anti-HSP90 agent Onalespib (OP-163). EANM’17. Eur J Nucl Med Mol Imaging. 2017.

30.

Lundsten S, Spiegelberg D, Stenerlow B, Nestor M. The HSP90 inhibitor onalespib potentiates 177Lu-DOTATATE therapy in neuroendocrine tumor cells. Int J Oncol. 2019;55(6):1287–95.PubMedPubMedCentral

31.

Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–5.CrossRefPubMedPubMedCentral

32.

Canella A, Welker AM, Yoo JY, Xu J, Abas FS, Kesanakurti D, et al. Efficacy of onalespib, a long-acting second-generation HSP90 inhibitor, as a single agent and in combination with temozolomide against malignant gliomas. Clin Cancer Res. 2017;23(20):6215–26. https://doi.org/10.1158/1078-0432.CCR-16-3151.CrossRefPubMedPubMedCentral

33.

Spiegelberg D, Mortensen AC, Selvaraju RK, Eriksson O, Stenerlow B, Nestor M. Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model. Eur J Nucl Med Mol Imaging. 2016;43(5):974–82. https://doi.org/10.1007/s00259-015-3260-x.CrossRefPubMed

34.

Dalmo J, Rudqvist N, Spetz J, Laverman P, Nilsson O, Ahlman H, et al. Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2. Oncol Rep. 2012;27(1):174–81. https://doi.org/10.3892/or.2011.1494.CrossRefPubMed

35.

Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kolby L, Schmitt J, et al. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm. 2003;18(4):593–9. https://doi.org/10.1089/108497803322287682.CrossRefPubMed

36.

de Araujo EB, Caldeira Filho JS, Nagamati LT, Muramoto E, Colturato MT, Couto RM, et al. A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours. Appl Radiat Isot. 2009;67(2):227–33. https://doi.org/10.1016/j.apradiso.2008.09.009.CrossRefPubMed

37.

de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92(5):628–33. https://doi.org/10.1002/1097-0215(20010601)92:5<628::aid-ijc1244>3.0.co;2-l.CrossRefPubMed

38.

Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5). https://doi.org/10.3390/cancers9050052.

39.

Rolleman EJ, Krenning EP, Bernard BF, de Visser M, Bijster M, Visser TJ, et al. Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats. Eur J Nucl Med Mol Imaging. 2007;34(2):219–27. https://doi.org/10.1007/s00259-006-0232-1.CrossRefPubMed

Title: The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
Authors: Sara Lundsten
Diana Spiegelberg
Nakul R. Raval
Marika Nestor
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Keyword: Neuroendocrine Tumor
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04673-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The radiosensitizer Onalespib increases complete remission in ¹⁷⁷Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety

Correction to: A multiparametric analysis based on DCE-MRI to improve the accuracy of parotid tumor discrimination

Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort

Noninvasive PET tracking of post-transplant gut microbiota in living mice

Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumors

Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE